Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice
Purpose of Review Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly nonalcoholic fatty liver disease (NAFLD), is the most common chronic liver disease affecting 30% of the global population. In this article, we summarize current expert guidelines, review clinical practice implications, and provide insight into the utility of non-invasive tests (NITs). Recent Findings The burden of MASLD is growing with the obesity epidemic, yet disease awareness and diagnosis is low. Patients can progress to metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), which can advance to liver fibrosis, cirrhosis, hepatic decompensation, and liver cancer. NITs help identify high-risk patients who may benefit from specialty referral and MASH-directed therapy. Summary Global societies offer various recommendations for the screening and diagnosis of MASLD utilizing evidence-based, widely accessible methods such as serum indices, NITs, and liver biopsy. Several targeted steatotic liver disease (SLD) screening tools and novel therapies are under development..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Current gastroenterology reports - 25(2023), 10 vom: 28. Sept., Seite 213-224 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ilagan-Ying, Ysabel C. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s11894-023-00883-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR053696522 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR053696522 | ||
| 003 | DE-627 | ||
| 005 | 20231111064649.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231111s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11894-023-00883-8 |2 doi | |
| 035 | |a (DE-627)SPR053696522 | ||
| 035 | |a (SPR)s11894-023-00883-8-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ilagan-Ying, Ysabel C. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Purpose of Review Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly nonalcoholic fatty liver disease (NAFLD), is the most common chronic liver disease affecting 30% of the global population. In this article, we summarize current expert guidelines, review clinical practice implications, and provide insight into the utility of non-invasive tests (NITs). Recent Findings The burden of MASLD is growing with the obesity epidemic, yet disease awareness and diagnosis is low. Patients can progress to metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), which can advance to liver fibrosis, cirrhosis, hepatic decompensation, and liver cancer. NITs help identify high-risk patients who may benefit from specialty referral and MASH-directed therapy. Summary Global societies offer various recommendations for the screening and diagnosis of MASLD utilizing evidence-based, widely accessible methods such as serum indices, NITs, and liver biopsy. Several targeted steatotic liver disease (SLD) screening tools and novel therapies are under development. | ||
| 650 | 4 | |a Nonalcoholic fatty liver disease |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Metabolic dysfunction-associated steatotic liver disease |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Metabolic syndrome |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Obesity |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Non-invasive testing |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Nonalcoholic steatohepatitis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a NAFLD fibrosis score |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Fibrosis-4 score |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Banini, Bubu A. |4 aut | |
| 700 | 1 | |a Do, Albert |4 aut | |
| 700 | 1 | |a Lam, Robert |4 aut | |
| 700 | 1 | |a Lim, Joseph K. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current gastroenterology reports |d Philadelphia, Pa. : Current Science Inc., 1999 |g 25(2023), 10 vom: 28. Sept., Seite 213-224 |w (DE-627)SPR022906746 |w (DE-600)2094160-2 |x 1534-312X |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:10 |g day:28 |g month:09 |g pages:213-224 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11894-023-00883-8 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2023 |e 10 |b 28 |c 09 |h 213-224 | ||